Form 4: Immix Biopharma CEO and Chairman Ilya Rachman Increases Stake with Recent Stock Purchase

Immix Biopharma's CEO and Chairman, Ilya Rachman, recently purchased 2,178 shares of the company's common stock, increasing his beneficial ownership.

Summary

• Ilya M. Rachman, the CEO and Chairman of Immix Biopharma, Inc. (IMMX), acquired 2,178 shares of common stock.
• The transaction occurred on June 18, 2025, at a volume-weighted average price of $2.295 per share.
• Following this purchase, Mr. Rachman's direct beneficial ownership of Immix Biopharma common stock increased to 1,138,437 shares.
• The filing indicates that the transaction was made pursuant to a Rule 10b5-1(c) plan, which allows insiders to set up a predetermined plan for buying or selling securities to avoid accusations of insider trading.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the insider purchase by the CEO and Chairman, indicating management's confidence in the company. However, it's a single transaction and not a comprehensive financial report, hence not an extremely high score.

Positives

• The purchase by CEO and Chairman Ilya Rachman signals confidence in the company's future prospects and valuation.
• Insider buying, especially by top executives, is often viewed positively by investors as it aligns management's interests with those of shareholders.

Future Outlook

The document does not contain explicit forward-looking statements or guidance regarding the company's future financial performance or strategic direction. The transaction itself, however, can be interpreted as a positive signal regarding management's internal outlook.

Management Comments

• The reporting person, Ilya Rachman, undertakes to provide full information regarding the number of shares and prices at which the transaction was effected upon request to the SEC staff, the Issuer, or a security holder.

Industry Context

Insider purchases in the biotechnology sector, particularly by key executives like the CEO and Chairman, can be a significant indicator of internal confidence, especially given the inherent risks and long development cycles in the industry. Such transactions often suggest that management believes the company's stock is undervalued or that significant positive developments are anticipated.

Stakeholder Impact

• Shareholders: The purchase by a key executive may instill greater confidence among existing shareholders and potentially attract new investors, as it signals strong belief in the company's future from within.

Key Dates

Recommendation

Keywords

Immix Biopharma, IMMX, Ilya Rachman, Insider Purchase, Form 4, CEO, Chairman, Stock Acquisition, Beneficial Ownership, Biopharma